Trial Profile
A randomized, double blind placebo-controlled multicenter study of the efficacy and safety of dupilumab in patients with moderate to severe hand eczema refractory to highly potent topical corticosteroids
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Eczema
- Focus Therapeutic Use
- Acronyms DUPECZEMAIN
- 22 Aug 2023 Planned End Date changed from 1 Jun 2022 to 1 Jun 2024.
- 22 Aug 2023 Planned primary completion date changed from 1 Jan 2022 to 1 Jan 2024.
- 03 Sep 2021 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.